On Jul. 9, 2020, Altimmune announced that it had entered into a teaming agreement with DynPort Vaccine Company (DVC), a General Dynamics Information Technology (GDIT) company, to coordinate U.S. Government funding efforts and, if successful, to provide program management, drug development activity integration, and regulatory support for AdCOVID, Altimmuneﾒs single-dose intranasal COVID-19 vaccine candidate.